Clinical trial
Effect of Risk Factors Likely to Influence Immuno of Combined Hepatitis A & B…
NCT00289731 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00289731 |
|---|---|
| Title | Effect of Risk Factors Likely to Influence Immuno of Combined Hepatitis A & B Vacc vs Monovalent Hepatitis A & B Vacc |
| Official title | Evaluate the Effect of Several Risk Factors That Are Likely to Influence the Immunogenicity of GSK Biologicals' Combined Hepatitis A & B Vaccine, vs Separately Administered Monovalent Hepatitis A and Hepatitis B Vaccines |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Hepatitis B, Hepatitis A |
| Intervention type | Biological |
| Interventions | TWINRIX™, Engerix™-B, HAVRIX™, HB VAX PRO™, Vaqta™ |
| Enrollment | 596 |
| Start date | Nov 24, 2003 |
| Primary completion | Dec 21, 2004 |
| Completion | Dec 21, 2004 |
| First posted | Feb 10, 2006 |
| Last update posted | Nov 15, 2019 |
| Countries | Belgium, Czechia, Germany |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: